Radionuclide therapy (RNT) is a rapidly emerging class of oncology agents for metastatic castration-resistant prostate cancer (PC), spurred by Food and Drug Administration approval of 223Ra-dichloride and 177Lu-PSMA-617. Here, FOLH1 is linked to pachyonychia congenita.